The Relation between Lower Respiratory Tract Bacterial Flora and Clinical Index of Bronchiectasis Patients without CF and the Impact of Immunomodulator( Pneumonia?Vaccine and ?Erythromycin )

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011312

Enrollment

Unknown

Registered

2017-05-06

Start date

2017-05-15

Completion date

Unknown

Last updated

2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-CF bronchiectasis

Interventions

A:use of expectorants as routine treatment

B:7mg every morning for 10 days, and then stop for 20 days

repeat the treatment for 3 months and then stop for 3 months

C:long-term use of erythromycin, 125mg every day

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. History of recurrent cough, expectoration and hemoptysis; 2. Diagnosed as non-CF bronchiectasis according to HRCT and clinicians; 3. Non-smokers, aged 18 to 85 years old.

Exclusion criteria

Exclusion criteria: 1. Complicated with asthma, tuberculosis, COPD and idiopathic pulmonary fibrosis; 2. History of allergy diseases; 3. History of acute or chronic cardiovascular, liver, renal or malignant tumor diseases; 4. The use of glucocorticoid within 3 months; 5. Hard to cooperation and coordination.

Design outcomes

Primary

Measure	Time frame
the frequency of acute episo;pulmonary function;HRCT;LCQ;SGRQ;	—

Secondary

Measure	Time frame
cytokines;CRP;	—

Countries

China

Contacts

Public ContactShao Changzhou

Zhongshan Hospital Fudan University

shao.changzhou@zs-hospital.sh.cn+86 13564698386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026